mProX™ Human PIK3CA Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX431	Magic™ Human PIK3CA/PIK3R1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;MCF-7

Target Classification

Kinase Cell Lines

Target Research Area

Immunology Research

Related Diseases

Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome; Congenital Lipomatous Overgrowth, Vascular Malformations, And Epidermal Nevi

Gene ID

Human:5290

UniProt ID

Human:P42336

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The applications of PIK3CA include its role as a targetable driver alteration in histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH). Activating mutations in PIK3CA have been shown to drive histiocytic neoplasms in vivo, and targeted inhibition of PI3K using the inhibitor alpelisib has demonstrated successful treatment of PIK3CA-mutated LCH. In endometrial cancer, the PIK3CA-PIK3R1-PTEN pathway is implicated in the pathogenesis of the disease, and alterations in ErbB receptors, including ErbB-2, are observed in aggressive histologic subtypes, suggesting a potential role for ErbB-targeted therapies in these subgroups. In cervical cancer, cervical cancers carrying PIK3CA helical domain mutations exhibit redox adaptation and resistance to therapy. SGK3, activated upon oxidative stress, promotes cell growth and drug resistance by stabilizing and activating the antioxidant enzyme catalase. In anal cancer, preclinical models have been developed to assess anal cancer treatments, including combined-modality therapy (CMT) with radiation and chemotherapy. These models have shown increased survival with CMT treatment and the potential efficacy of LY3023414, a drug effective in cancer prevention, in reducing tumor size. Overall, these studies highlight the diverse applications of PIK3CA in various cancer types and the potential for targeted therapies.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PIK3CA Stable Cell Line (S01YF-1023-PY53). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Brown (Verified Customer)

Can PIK3CA mutations generate immunogenic neoantigens? Jan 20 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Mutant PIK3CA can generate immunogenic public neoantigens, which may be targeted for cancer immunotherapy. Jan 20 2020

chat Jordan Brown (Verified Customer)

What is the role of PIK3CA mutations in PIK3CA-related overgrowth spectrum disorders? Aug 03 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

PIK3CA mutations contribute to a variety of overgrowth spectrum disorders, with molecular diagnostic yield increasing when multiple tissues are tested. Aug 03 2022

Published Data

Fig.1 A measurable reduction in membrane PDK1 levels under serum-starved conditions was observed as a consequence of PIK3CA expression reduction through the use of two independent shRNAs in MCF-7 cells.

Immunoblotting analyses were conducted on cytosolic (Cy) and membrane (M) fractions that had been prepared subsequent to the introduction of shRNA-mediated knockdown targeting p110a (sh-PIK3CA) or a control (sh-GFP) within serum-starved MCF-7 cells. A discernible reduction in membrane PDK1 was observed in serum-starved MCF-7 cells as a consequence of PIK3CA expression diminishment through the utilization of two independent shRNAs.

Ref: Vasudevan, Krishna M., et al. "AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer." Cancer cell 16.1 (2009): 21-32.

Pubmed: 19573809

DOI: 10.1016/j.ccr.2009.04.012

Research Highlights

Owusu-Adjei, Brittany. et al. "Diffusely invasive supratentorial rosette-forming glioneuronal tumor: illustrative case." Journal of neurosurgery. Case lessons, 2023.
Rosette-forming glioneuronal tumors (RGNTs) are a rare type of tumor that consists of a combination of glial and neurocytic components. They are typically found in the posterior fossa, specifically around the fourth ventricle, in young adults. However, in some cases, they may extend to the supratentorial region, posing difficulties in diagnosis, surgical treatment, and predicting outcomes.
Owusu-Adjei, Brittany. et al. "Diffusely invasive supratentorial rosette-forming glioneuronal tumor: illustrative case." Journal of neurosurgery. Case lessons, 2023.
Pubmed: 37870758 DOI: 10.3171/CASE23435

Wang, Min. et al. "The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance." Redox biology, 2023.
The aberrant redox homeostasis and adaptation to oxidative stress exhibited by cancer cells can be exploited for therapeutic benefit by disrupting redox adaptation. A study by the authors revealed that the protein SGK3 functions as an anti-oxidative factor in cervical cancers with PIK3CA helical domain mutations. Upon activation by oxidative stress, SGK3 stabilizes and activates the antioxidant enzyme catalase, which protects cells from reactive oxygen species (ROS). SGK3 also phosphorylates GSK3Œ≤, inhibiting its ability to promote the ubiquitination and degradation of catalase. In addition, inhibiting SGK3 enhances the effectiveness of the CDK4/6 inhibitor Palbociclib and overcomes cisplatin resistance through ROS-mediated mechanisms. These findings highlight the potential of targeting the SGK3-catalase antioxidant signaling axis for therapeutic benefit in cervical cancers with PIK3CA helical domain mutations.
Wang, Min. et al. "The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance." Redox biology, 2023.
Pubmed: 37866161 DOI: 10.1016/j.redox.2023.102931